A prospective, open label, multicenter, efficacy and safety study of several infusions of Promethera HepaStem in Urea Cycle Disorders pediatric patients.
Phase of Trial: Phase II/III
Latest Information Update: 30 Sep 2017
Price : $35 *
At a glance
- Drugs Mesenchymal stem cell therapy (Primary)
- Indications Inborn urea cycle disorders
- Focus Therapeutic Use
- Sponsors Promethera Biosciences
- 11 Mar 2017 This trial has been discontinued in Poland as per European Clinical Trials Database record.
- 15 Oct 2016 According to Promethera Biosciences media release, company receives approval in Belgium to enroll patients in the study.
- 26 Sep 2014 New trial record